(Q38843694)

6 September 2017

1 reference

title

A Review of Treatment Options for Progressive Supranuclear Palsy (English)

1 reference

6 September 2017

1

Maria Stamelou

1 reference

6 September 2017

Günter Höglinger

2

1 reference

6 September 2017

publication date

24 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

30

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

629-636

1 reference

PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

New insights into progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Atypical parkinsonism: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Appoptosin is a novel pro-apoptotic protein and mediates cell death in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Interventions in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Clinicopathological study in progressive supranuclear palsy with pedunculopontine stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Diagnosis and management of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy: analysis of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Treatment of progressive supranuclear palsy and corticobasal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Current and future treatments in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Levodopa-induced facial dystonia in a case of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy: progression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Current and future therapeutic approaches in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Therapeutic advances in multiple system atrophy and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Methysergide in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Treatment of progressive supranuclear palsy with methysergide. A clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Idazoxan treatment in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Treatment of progressive supranuclear palsy with tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Donepezil in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Botulinum A toxin for the so-called apraxia of lid opening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

"Apraxia of lid opening," a focal eyelid dystonia: clinical study of 32 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Bilateral pedunculopontine nucleus stimulation for progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Mitochondrial dysfunction in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Further evidence for mitochondrial dysfunction in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Transmission and spreading of tauopathy in transgenic mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Brain homogenates from human tauopathies induce tau inclusions in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Vaccination as a therapeutic approach to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Tau silencing by siRNA in the P301S mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Zolpidem in Progressive Supranuclear Palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0347-2

Fluvoxamine for the treatment of depression and parkinsonism in progressive supranuclear palsy

21 January 2018

1 reference

12 December 2020

Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide

1 reference

12 December 2020

Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy

1 reference

12 December 2020

Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice

1 reference

12 December 2020

Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy

1 reference

12 December 2020

Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy

1 reference

12 December 2020

[Effects of tandospirone citrate on frozen gait in patients with early stage of progressive supranuclear palsy, investigated by walk-induced activation single photon emission computed tomography method]

1 reference

12 December 2020

Natural history and clinical features of progressive supranuclear palsy: a clinical study

1 reference

12 December 2020

"Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report.

1 reference

12 December 2020

The clinical and pathologic hallmarks of progressive supranuclear palsy.

1 reference

12 December 2020

Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains

1 reference

12 December 2020

Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration

1 reference

12 December 2020

Progressive supranuclear palsy in a sample of Brazilian population: clinical features of 16 patients

1 reference

12 December 2020

Pramipexole in progressive supranuclear palsy

1 reference

12 December 2020

Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?

1 reference

12 December 2020

Pharmacological Therapy in Progressive Supranuclear Palsy

1 reference

12 December 2020

Retrospective study of drug response in 87 patients with progressive supranuclear palsy

1 reference

12 December 2020

Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy

1 reference

12 December 2020

Progressive supranuclear palsy: clinical features and response to treatment in 16 patients

1 reference

12 December 2020

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

1 reference

12 December 2020

Muscle mitochondrial ATP production in progressive supranuclear palsy

1 reference

12 December 2020

Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration

1 reference

12 December 2020

Botulinum toxin-A improves the rigidity of progressive supranuclear palsy

1 reference

12 December 2020

Cholinergic systems in progressive supranuclear palsy

1 reference

12 December 2020

Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies

1 reference

12 December 2020

10.1007/S40263-016-0347-2

Identifiers

DOI

1 reference

6 September 2017

1 reference